{"id":14130,"date":"2021-09-25T06:57:46","date_gmt":"2021-09-25T06:57:46","guid":{"rendered":"https:\/\/zeepedia.com\/?p=14130"},"modified":"2021-10-23T11:14:36","modified_gmt":"2021-10-23T11:14:36","slug":"ilaris","status":"publish","type":"post","link":"https:\/\/zeepedia.com\/medical\/medicines\/ilaris\/","title":{"rendered":"Ilaris &#8211; Canakinumab uses, dose and side effects"},"content":{"rendered":"\n<p>150 mg \/ ml&nbsp;injection&nbsp;solution<br>canakinumab<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">1. What Ilaris is and what it is used for<\/h2>\n\n\n\n<p><strong>What Ilaris is<\/strong><\/p>\n\n\n\n<p>Ilaris contains the active substance kanakinumab, a monoclonal&nbsp;antibody, which belongs to a group of medicines called interleukin inhibitors.&nbsp;It blocks the effect of a substance in the body called&nbsp;interleukin&nbsp;1-beta (IL 1-beta), which is found in increasing amounts in inflammatory diseases.<\/p>\n\n\n\n<p><strong>What Ilaris is used for<\/strong><\/p>\n\n\n\n<p>Ilaris is used to treat the following inflammatory diseases:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Periodic fever syndromes:<ul><li>Cryopyrin-Associated Periodic Syndrome (CAPS),<\/li><li>Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS),<\/li><li>Hyperimmunoglobulin D syndrome (HIDS) \/ mevalonate kinase deficiency (MKD),<\/li><li>Familial Mediterranean fever (FMF).<\/li><\/ul><\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li>Still&#8217;s disease including Still&#8217;s disease in adults (AOSD) and systemic&nbsp;juvenile idiopathic arthritis&nbsp;(sJIA)<\/li><li>Rheumatoid arthritis<\/li><\/ul>\n\n\n\n<p>Further information on each of these diseases is given below.<\/p>\n\n\n\n<p>Periodic fever syndromes<\/p>\n\n\n\n<p>Ilaris is used in adults and children aged 2 years and older to treat the following:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Cryopyrin-Associated Periodic Syndrome (CAPS) &#8211; this is a group of autoinflammatory diseases, which include:<ul><li>Muckle-Wells Syndrome (MWS),<\/li><li>systemic&nbsp;inflammatory&nbsp;disease with&nbsp;neonatal&nbsp;onset (NOMID), also known as chronic neurological skin and joint syndrome in children (CINCA),<\/li><li>severe forms of familial autoinflammatory cold syndrome (FCAS) \/ familial cold urticaria (FCU), which appear with additional signs and symptoms than those found in urticaria-induced colds.<\/li><\/ul><\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li>Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS),<\/li><li>Hyperimmunoglobulin D syndrome (HIDS) also known as mevalonate kinase deficiency (MKD)<\/li><li>Familial Mediterranean Fever (FMF): Ilaris is used to treat FMF.&nbsp;Ilaris can be used with colchicine, if appropriate.<\/li><\/ul>\n\n\n\n<p>In patients with periodic fever syndrome (CAPS, TRAPS, HIDS \/ MKD, and FMF), the body produces too much IL 1-beta.&nbsp;This can lead to fever, headache, fatigue, skin rash, or joint and muscle pain.&nbsp;By blocking the activity of IL 1-beta, Ilaris can improve these symptoms.<\/p>\n\n\n\n<p><strong>Contact a doctor immediately<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>If you have ever had an atypical rash or dandruff after taking Ilaris.<br>The severe skin reaction DRESS (drug reaction with&nbsp;eosinophilia&nbsp;and systemic symptoms) has been reported rarely in association with treatment with Ilaris, particularly in patients with systemic&nbsp;juvenile idiopathic arthritis&nbsp;(sJIA).&nbsp;Seek medical attention immediately if you get an atypically widespread skin rash, which can occur in combination with high body temperature and enlarged&nbsp;lymph nodes&nbsp;.<\/li><\/ul>\n\n\n\n<p>Still illness<\/p>\n\n\n\n<p>Ilaris is used in adults, adolescents, and children to treat active Stills disease including Stills disease in adults (AOSD) and systemic&nbsp;juvenile idiopathic arthritis&nbsp;(sJIA) in patients aged 2 years and older if other treatments have not worked well enough.&nbsp;Ilaris can be used alone or in combination with methotrexate.<\/p>\n\n\n\n<p>Still, &#8216;s diseases including sJIA and AOSD are inflammatory diseases.&nbsp;They can cause pain, swelling, and&nbsp;inflammation&nbsp;in one or more joints, as well as rash and fever.&nbsp;A pro-inflammatory&nbsp;protein&nbsp;called IL 1-beta plays an important role in the inflammatory processes in Still&#8217;s disease.&nbsp;Ilaris blocks the activity of IL 1-beta, which may improve the signs and symptoms of Still&#8217;s disease.<\/p>\n\n\n\n<p>Rheumatoid arthritis<\/p>\n\n\n\n<p>Ilaris is used in adults to treat the symptoms of frequent rheumatoid arthritis attacks if other treatments have not had sufficient effect.<\/p>\n\n\n\n<p>Gouty arthritis is caused by the formation of urate crystals.&nbsp;These crystals cause large amounts of IL 1-beta to form, which in turn can lead to symptoms such as sudden and severe pain,&nbsp;redness, feeling hot, and swelling in a joint (a so-called gout attack).&nbsp;By blocking the activity of IL 1-beta, Ilaris may lead to an improvement in these symptoms.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">2. What you need to know before using Ilaris<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Do not use Ilaris<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>If you are allergic to kanakinumab or any of the other ingredients of this medicine (listed in section 6).<\/li><li>If you have one or suspect you have an active and severe&nbsp;infection&nbsp;.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Warnings and cautions<\/h2>\n\n\n\n<p><strong>Talk to your doctor before using Ilaris<\/strong>&nbsp;if any of the following apply to you:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>If you currently have an&nbsp;infection&nbsp;or if you have previously had repeated&nbsp;infections&nbsp;or if you have a condition that makes it easier for you to get an&nbsp;infection&nbsp;, such as&nbsp;low content of&nbsp;white blood cells&nbsp;.<\/li><li>If you have or have had&nbsp;tuberculosis&nbsp;or have been in direct contact with a person with an ongoing tuberculosis infection.&nbsp;Your doctor must check if you have&nbsp;tuberculosis&nbsp;by performing a special test.<\/li><li>If you have signs of a liver problem, such as yellowing of the skin and eyes, nausea, decreased appetite, dark urine and light stools.<\/li><li>If you need to be vaccinated.&nbsp;It is recommended that you avoid certain types of vaccines (live vaccines) while you are being treated with Ilaris (see also \u201cOther medicines and Ilaris\u201d).<\/li><\/ul>\n\n\n\n<p>Still illness<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Patients with Still&#8217;s disease can develop a condition called macrophage activation syndrome (MAS), which can be life-threatening.&nbsp;Your doctor will monitor you for potential triggers of MAS that include&nbsp;infection&nbsp;and reactivation of the underlying Stills disease (&nbsp;relapse&nbsp;).<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Children and young people<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>CAPS, TRAPS, HIDS \/ MKD, FMF and sJIA:<\/strong>&nbsp;Ilaris can be given to children aged 2 years and older.<\/li><li><strong>Gouty arthritis:<\/strong>&nbsp;Ilaris is not recommended for children or adolescents under 18 years.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Other medicines and Ilaris<\/h2>\n\n\n\n<p>Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Live vaccines: You are advised to avoid being vaccinated with a certain type of vaccine, so-called &#8220;live vaccines&#8221;, while you are being treated with Ilaris.&nbsp;Your doctor may want to check which vaccinations you have received in the past and give you all the vaccinations you are missing before starting treatment with Ilaris.&nbsp;If you need to get a live vaccine after starting treatment with Ilaris, discuss this with your doctor.&nbsp;A live vaccine should normally be given at least 3 months after your last&nbsp;injection&nbsp;of Ilaris and 3 months before the next one.<\/li><li>Drugs called&nbsp;tumor necrosis factor&nbsp;(&nbsp;TNF&nbsp;) inhibitors, e.g.&nbsp;etanercept, adalimumab or infliximab.&nbsp;These are mainly used in rheumatic and autoimmune diseases, they should not be used with Ilaris as it may increase the risk of&nbsp;infection&nbsp;.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Pregnancy and breastfeeding<\/h2>\n\n\n\n<p>If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>You are advised to avoid becoming pregnant and must use appropriate contraception while using Ilaris and for at least 3 months after the last treatment with Ilaris.&nbsp;It is important that you tell your doctor if you are pregnant, think you may be pregnant or are planning to have a baby.&nbsp;Your doctor will talk to you about the possible risk of taking Ilaris during pregnancy.<\/li><li>If you were given kanakinumab while you were pregnant, it is important that you inform your child&#8217;s doctor or nurse before giving vaccinations to your child.&nbsp;Your baby should not receive live vaccines until&nbsp;at least&nbsp;16 weeks after receiving your last&nbsp;dose&nbsp;of kanakinumab before delivery.<\/li><li>It is not known if Ilaris passes into breast milk.&nbsp;Your doctor will talk to you about the possible risk of taking Ilaris while breast-feeding.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Driving and using machines<\/h2>\n\n\n\n<p>Treatment with Ilaris can cause a tingling sensation (dizziness or&nbsp;vertigo&nbsp;) or intense fatigue (&nbsp;asthenia&nbsp;), which may affect your ability to drive or use tools and machines.&nbsp;If you feel a tingling sensation or feel tired, do not drive or use any tools or machines until you feel normal again.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">3. How to use Ilaris<\/h2>\n\n\n\n<p>Always use this medicine exactly as your doctor has told you.&nbsp;If you are not sure, talk to your doctor, pharmacist, or nurse.<\/p>\n\n\n\n<p>Tell your doctor about your health condition and any symptoms before taking or receiving Ilaris (see section 2).&nbsp;If necessary, your doctor may decide to postpone or discontinue your treatment.<\/p>\n\n\n\n<p>Ilaris should be given&nbsp;subcutaneously.&nbsp;This means that it should be injected with a short needle into the adipose tissue just under the skin.<\/p>\n\n\n\n<p>If you have gouty arthritis, your treatment will be monitored by a specialist.&nbsp;Ilaris should then only be injected by healthcare professionals.<\/p>\n\n\n\n<p>If you have CAPS or Still&#8217;s disease (AOSD or sJIA), you can give yourself an&nbsp;injection&nbsp;with Ilaris when you have received proper training or a caregiver can inject it for you.<\/p>\n\n\n\n<p><strong>How much Ilaris to use<\/strong><\/p>\n\n\n\n<p>Cryopyrin-Associated Periodic Syndrome (CAPS)<\/p>\n\n\n\n<p>The recommended starting dose of Ilaris is:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><em>Adults, adolescents and children from 4 years of age<\/em><ul><li>150 mg for patients weighing over 40 kg<\/li><li>2 mg \/ kg for patients weighing between 15 kg and 40 kg<\/li><li>4 mg \/ kg for patients weighing between 7.5 kg and less than 15 kg<\/li><\/ul><\/li><li><em>Children aged 2 or 3 years<\/em><ul><li>4 mg \/ kg for patients weighing 7.5 kg or more<\/li><\/ul><\/li><\/ul>\n\n\n\n<p>Ilaris is injected every 8 weeks as a single dose.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>If you have not responded well enough to the treatment after 7 days, your doctor may give you an additional&nbsp;dose&nbsp;of 150 mg or 2 mg \/ kg.<\/li><li>If you respond well enough to the second&nbsp;dose&nbsp;one, treatment will be continued at 300 mg or 4 mg \/ kg every 8 weeks.<\/li><li>If you do not respond well enough to the increased&nbsp;dose&nbsp;, a third&nbsp;dose of&nbsp;Ilaris of 300 mg or 4 mg \/ kg may be given.<\/li><li>If you respond well enough to the third&nbsp;dose&nbsp;, your treatment may be continued at 600 mg or 8 mg \/ kg every 8 weeks.<\/li><\/ul>\n\n\n\n<p>For children who have received a starting dose of 4 mg\/kg and who have not responded well enough after 7 days, the doctor may give a second&nbsp;dose&nbsp;of 4 mg\/kg.&nbsp;If the child then responds well enough to this, treatment can be continued at 8 mg\/kg every 8 weeks.<\/p>\n\n\n\n<p>Tumor necrosis factor receptor-associated periodic syndrome (TRAPS), Hyper immunoglobulin D syndrome (HIDS) \/ mevalonate kinase deficiency (MKD), and Familial Mediterranean fever (FMF)<\/p>\n\n\n\n<p>The recommended starting dose of Ilaris is:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><em>Adults and children aged 2 years or older<\/em><ul><li>150 mg for patients weighing more than 40 kg<\/li><li>2 mg \/ kg for patients weighing between 7.5 kg and less than 40 kg<\/li><\/ul><\/li><\/ul>\n\n\n\n<p>Ilaris is injected every 4 weeks as a single dose.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>If you have not responded well enough to the treatment after 7 days, your doctor may give you an additional&nbsp;dose&nbsp;of 150 mg or 2 mg \/ kg.<\/li><li>If you respond well enough to this, treatment will be continued at 300 mg or 4 mg \/ kg every 4 weeks.<\/li><\/ul>\n\n\n\n<p>Still&#8217;s a disease (sJIA and AOSD)<\/p>\n\n\n\n<p>The recommended&nbsp;dose is&nbsp;one of Ilaris with Still&#8217;s disease with a body weight of 7.5 kg and above is 4 mg\/kg (up to a maximum of 300 mg).&nbsp;Ilaris is injected every 4 weeks as a single dose.<\/p>\n\n\n\n<p>Rheumatoid arthritis<\/p>\n\n\n\n<p>Your doctor will discuss with you if a urate-lowering treatment needs to be started or adjusted to lower the uric acid level in your blood.<\/p>\n\n\n\n<p>The recommended&nbsp;dose&nbsp;of Ilaris for adult patients with gouty arthritis is 150 mg as a single dose during an attack.<\/p>\n\n\n\n<p>If you need another treatment with Ilaris and provided that the last treatment worked, you must wait at least 12 weeks before receiving the next&nbsp;dose.<\/p>\n\n\n\n<p><strong>How to inject Ilaris on yourself or a patient<\/strong><\/p>\n\n\n\n<p>If you are a patient with CAPS, TRAPS, HIDS \/ MKD, or Still&#8217;s a disease (AOSD or sJIA) or a health care provider for patients with any of these conditions, you can give the&nbsp;injection&nbsp;you Ilaris yourself After proper training in the correct injection technique.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>The patient or caregiver and the doctor should decide together who should give the&nbsp;injections&nbsp;with Ilaris.<\/li><li>The doctor or nurse will show you how to give&nbsp;the injection&nbsp;you with Ilaris.<\/li><li>Do not try to&nbsp;inject&nbsp;yourself if you have not received adequate training or if you are not sure how to do it.<\/li><li>Ilaris 150 mg \/ ml&nbsp;injection&nbsp;solution supplied in a&nbsp;vial&nbsp;for single use to a patient.<\/li><li>Never reuse leftover solution.<\/li><\/ul>\n\n\n\n<p>For instructions on how to perform&nbsp;the injection&nbsp;with Ilaris, read the &#8220;User Manual&#8221; at the end of this leaflet.&nbsp;If you have any further questions, ask your doctor, pharmacist, or nurse.<\/p>\n\n\n\n<p><strong>How long to use Ilaris<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>CAPS, TRAPS, HIDS \/ MKD, FMF or Still&#8217;s disease (AOSD or sJIA): Your<\/strong>&nbsp;doctor will decide how long you should continue with Ilaris.<\/li><li><strong>Gouty arthritis:<\/strong>&nbsp;If you have a gouty arthritis attack, you will receive Ilaris as a single dose.&nbsp;If you get another attack, your doctor may consider giving you a new&nbsp;dose of&nbsp;Ilaris, but not earlier than 12 weeks after the first&nbsp;dose&nbsp;.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">If you use more Ilaris than you should<\/h2>\n\n\n\n<p>If you have accidentally injected more Ilaris than the recommended&nbsp;dose, it is probably not that serious, but you should still inform your doctor, pharmacist, or nurse as soon as possible.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you forget to use Ilaris<\/h2>\n\n\n\n<p>If you have CAPS, TRAPS, HIDS \/ MKD, FMF, or Stills disease (AOSD or sJIA) and forgot to inject one&nbsp;dose&nbsp;of Ilaris, inject the next&nbsp;dose&nbsp;as soon as you remember.&nbsp;Then talk to your doctor about when to inject the next&nbsp;dose.&nbsp;You should then continue with the&nbsp;injections&nbsp;at the recommended interval, as before.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you stop using Ilaris<\/h2>\n\n\n\n<p>Discontinuing your treatment with Ilaris may make your condition worse.&nbsp;Do not stop taking Ilaris unless your doctor tells you to.<\/p>\n\n\n\n<p>If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">4. Possible side effects<\/h2>\n\n\n\n<p>Like all medicines, this medicine can cause&nbsp;side effects, although not everybody gets them.&nbsp;<\/p>\n\n\n\n<p><strong>Some&nbsp;side effects&nbsp;can be serious.&nbsp;Tell your doctor immediately if you notice any of the&nbsp;side effects&nbsp;below:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Fever that lasts longer than 3 days or other symptoms that indicate a serious&nbsp;infection&nbsp;.&nbsp;These can be tremors, chills, malaise, loss of appetite, body aches, usually associated with a sudden illness, sore throat or sore mouth, cough, mucus, chest pain, difficulty breathing, ear pain, persistent headache or local redness, feeling hot or swollen or&nbsp;inflamed.&nbsp;in the connective tissue (&nbsp;cellulite&nbsp;).&nbsp;These symptoms may be due to a serious&nbsp;infection&nbsp;, an unusual&nbsp;infection&nbsp;(&nbsp;opportunistic infection&nbsp;) or may be related to low levels of&nbsp;white blood cells&nbsp;(called&nbsp;leukopenia&nbsp;or&nbsp;neutropenia).).&nbsp;Your doctor may check your blood regularly if it is considered necessary.<\/li><li>Allergic reactions with rash and&nbsp;itching&nbsp;and possibly also&nbsp;hives&nbsp;, difficulty breathing or swallowing, dizziness, palpitations or low&nbsp;blood pressure&nbsp;.<\/li><\/ul>\n\n\n\n<p><strong>Other&nbsp;side effects&nbsp;of Ilaris can be:<\/strong><\/p>\n\n\n\n<p><strong>Very common<\/strong>&nbsp;(may affect more than 1 in 10 people):<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Infection&nbsp;is of all kinds.&nbsp;These may include:<ul><li>Respiratory tract infections such as&nbsp;pneumonia&nbsp;,&nbsp;influenza&nbsp;, sore throat, runny nose, nasal congestion, sneezing, feeling of pressure or pain in cheeks or forehead with or without fever (&nbsp;pneumonia&nbsp;,&nbsp;bronchitis&nbsp;,&nbsp;influenza&nbsp;, sinusitis,&nbsp;rhinitis&nbsp;,&nbsp;pharyngitis&nbsp;,&nbsp;tonsillitis&nbsp;,&nbsp;nasopharyngitis&nbsp;), upper respiratory tract.<\/li><li>Other&nbsp;infections&nbsp;such as ear infection, skin infection (&nbsp;cellulite&nbsp;), stomach pain and malaise (&nbsp;gastroenteritis&nbsp;) and painful and frequent urination with or without fever (urinary tract infection).<\/li><\/ul><\/li><li>Abdominal pain in the upper abdomen.<\/li><li>Joint pain (&nbsp;arthralgia&nbsp;).<\/li><li>Low level of&nbsp;white blood cells&nbsp;(&nbsp;leukopenia&nbsp;).<\/li><li>Deviating renal function values \u200b\u200b(decreased&nbsp;creatinine clearance&nbsp;,&nbsp;proteinuria&nbsp;).<\/li><li>Injection site reaction (such as&nbsp;redness&nbsp;, swelling, feeling hot and&nbsp;itching&nbsp;).<\/li><\/ul>\n\n\n\n<p><strong>Common<\/strong>&nbsp;(may affect up to 1 in 10 people):<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Candida&nbsp;&#8211;&nbsp;vaginal&nbsp;fungal infection (&nbsp;vulvovaginal&nbsp;candidiasis&nbsp;).<\/li><li>Dizziness, tingling sensation (&nbsp;vertigo&nbsp;).<\/li><li>Back pain or muscles.<\/li><li>Feeling weak or very tired (tiredness,&nbsp;asthenia&nbsp;).<\/li><li>Low levels of&nbsp;white blood cells&nbsp;that help prevent&nbsp;infection&nbsp;(&nbsp;neutropenia&nbsp;).<\/li><li>Abnormal blood triglyceride levels (disturbed fat metabolism).<\/li><li>Deviating liver function values \u200b\u200b(elevated&nbsp;transaminases&nbsp;) or high levels of&nbsp;bilirubin&nbsp;in the blood, with or without yellowing of the skin and eyes (hyperbilirubinemia).<\/li><\/ul>\n\n\n\n<p><strong>Uncommon<\/strong>&nbsp;(may affect up to 1 in 100 people):<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Heartburn (&nbsp;gastroesophageal reflux disease&nbsp;).<\/li><li>Low levels of&nbsp;blood cells&nbsp;that help prevent bleeding (&nbsp;platelets&nbsp;).<\/li><\/ul>\n\n\n\n<p>Tell your doctor or your child&#8217;s doctor immediately if you notice any of these symptoms.<\/p>\n\n\n\n<p><em>Reporting of side effects<\/em><\/p>\n\n\n\n<p>If you get any side effects, talk to your doctor, pharmacist, or nurse.&nbsp;This also applies to any side effects not mentioned in this information.&nbsp;You can also report side effects directly to the Medical Products Agency.&nbsp;By reporting side effects, you can help increase drug safety information.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">5. How to store Ilaris<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>Keep this medicine out of the sight and reach of children.<\/li><li>Do not use this medicine after the expiry date which is stated on the label and carton.&nbsp;The expiration date is the last day of the specified month.<\/li><li>Store in a refrigerator (2 \u00b0 C &#8211; 8 \u00b0 C).&nbsp;Do not freeze.<\/li><li>Keep the vial in the outer carton.&nbsp;Sensitive to light.<\/li><li>The solution should be used immediately after the first opening (piercing the rubber stopper) to prepare&nbsp;injection&nbsp;one.<\/li><li>Do not use this medicine if you notice that the solution is not ready for opalescence or if it contains particles.<\/li><li>Any unused product should be discarded after a&nbsp;single dose&nbsp;has been injected.<\/li><li>Medicines should not be disposed of via wastewater or household waste.&nbsp;Ask your pharmacist how to dispose of medicines no longer required.&nbsp;These measures will help to protect the environment.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">6. Contents of the packaging and other information<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Content declaration<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>The active substance is kanakinumab.&nbsp;One&nbsp;vial&nbsp;contains 150 mg kanakinumab in 1 ml solution.<\/li><li>The other ingredients are mannitol, histidine, histidine hydrochloride monohydrate, polysorbate 80, water for injections.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What the medicine looks like and contents of the pack<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>Ilaris is supplied as a&nbsp;solution for injection&nbsp;in a 2 ml&nbsp;glass&nbsp;vial&nbsp;.<\/li><li>The solution is a clear to opalescent liquid.&nbsp;It is colorless or may have a light brownish-yellow hue.&nbsp;Do not use if the liquid contains clearly visible particles, is cloudy or is clearly brown.<\/li><li>Ilaris is available in packs containing 1&nbsp;vial&nbsp;.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Marketing Authorisation Holder<\/h2>\n\n\n\n<p>Novartis Europharm Limited<\/p>\n\n\n\n<p>Vista Building<\/p>\n\n\n\n<p>Elm Park, Merrion Road<\/p>\n\n\n\n<p>Dublin 4<\/p>\n\n\n\n<p>Ireland<\/p>\n\n\n\n<p><strong>Manufacturer<\/strong><\/p>\n\n\n\n<p>Novartis Pharma GmbH<\/p>\n\n\n\n<p>Roonstrasse 25<\/p>\n\n\n\n<p>D-90429 Nuremberg<\/p>\n\n\n\n<p>Germany<\/p>\n\n\n\n<p>Contact the representative of the marketing authorization holder to find out more about this medicine:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Belgium \/ Belgique \/ Belgien<\/strong>Novartis Pharma NVTel: +32 2 246 16 11<\/td><td><strong>Lithuania<\/strong>SIA Novartis Baltics Lithuanian branchesTel: +370 5 269 16 50<\/td><\/tr><tr><td><strong>Bulgaria<\/strong>Novartis Bulgaria EOODTel .: +359 2 489 98 28<\/td><td><strong>Luxembourg \/ Luxemburg<\/strong>Novartis Pharma NVTel: +32 2 246 16 11<\/td><\/tr><tr><td><strong>Czech Republic<\/strong>Novartis sroTel: +420 225 775 111<\/td><td><strong>Hungary<\/strong>Novartis Hungary Kft.Tel: +36 1 457 65 00<\/td><\/tr><tr><td><strong>Denmark<\/strong>Novartis Healthcare A \/ STel: +45 39 16 84 00<\/td><td><strong>Malta<\/strong>Novartis Pharma Services Inc.Tel: +356 2122 2872<\/td><\/tr><tr><td><strong>Germany<\/strong>Novartis Pharma GmbHTel: +49 911 273 0<\/td><td><strong>The Netherlands<\/strong>Novartis Pharma BVTel: +31 88 04 52 111<\/td><\/tr><tr><td><strong>Eesti<\/strong>SIA Novartis Baltics Eesti subsidiaryTel: +372 66 30 810<\/td><td><strong>Norway<\/strong>Novartis Norge ASTel: +47 23 05 20 00<\/td><\/tr><tr><td><strong>Greece<\/strong>Novartis (Hellas) AEBE:\u0397\u03bb: +30 210 281 17 12<\/td><td><strong>Austria<\/strong>Novartis Pharma GmbHTel: +43 1 86 6570<\/td><\/tr><tr><td><strong>Spain<\/strong>Novartis Pharmac\u00e9utica, SATel: +34 93 306 42 00<\/td><td><strong>Poland<\/strong>Novartis Poland Sp.&nbsp;z ooTel .: +48 22 375 4888<\/td><\/tr><tr><td><strong>France<\/strong>Novartis Pharma SASTel: +33 1 55 47 66 00<\/td><td><strong>Portugal<\/strong>Novartis Farma &#8211; Pharmaceutical Products, SATel: +351 21 000 8600<\/td><\/tr><tr><td><strong>Croatia<\/strong>Novartis Hrvatska dooTel.&nbsp;+385 1 6274 220<\/td><td><strong>Romania<\/strong>Novartis Pharma Services Romania SRLTel: +40 21 31299 01<\/td><\/tr><tr><td><strong>Ireland<\/strong>Novartis Ireland LimitedTel: +353 1 260 12 55<\/td><td><strong>Slovenia<\/strong>Novartis Pharma Services Inc.Tel: +386 1 300 75 50<\/td><\/tr><tr><td><strong>Iceland<\/strong>Vistor hf.Phone: +354 535 7000<\/td><td><strong>Slovak Republic<\/strong>Novartis Slovakia sroTel: +421 2 5542 5439<\/td><\/tr><tr><td><strong>Italy<\/strong>Novartis Farma SpATel: +39 02 96 54 1<\/td><td><strong>Finland \/ Finland<\/strong>Novartis Finland OyPuh \/ Tel: +358 (0) 10 6133 200<\/td><\/tr><tr><td><strong>\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/strong>Novartis Pharma Services Inc.:\u0397\u03bb: +357 22 690 690<\/td><td><strong>Sweden<\/strong>Novartis Sverige ABTel: +46 8 732 32 00<\/td><\/tr><tr><td><strong>Latvia<\/strong>SIA Novartis BalticsTel: +371 67 887 070<\/td><td><strong>United&nbsp;<\/strong>&nbsp;<strong>Kingdom<\/strong>Novartis Pharmaceuticals UK Ltd.Tel: +44 1276 698370<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Ilaris contains the active substance kanakinumab, a monoclonal antibody, which belongs to a group of medicines called interleukin inhibitors. It blocks the effect of a substance in the body called interleukin 1-beta (IL 1-beta), which is found in increasing amounts in inflammatory diseases.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2200,12116],"tags":[13219,13225,13216,13220,13221,13222,13226,13227,13218,13224,13217,13223],"class_list":["post-14130","post","type-post","status-publish","format-standard","hentry","category-medicines","category-i","tag-benefits-of-canakinumab","tag-benefits-of-ilaris","tag-canakinumab","tag-canakinumab-injection","tag-canakinumab-side-effects","tag-ilaris","tag-ilaris-injection","tag-side-effects-of-ilaris","tag-what-canakinumab-is-used-for","tag-what-ilaris-is-used-for","tag-what-is-canakinumab","tag-what-is-ilaris"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/14130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=14130"}],"version-history":[{"count":5,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/14130\/revisions"}],"predecessor-version":[{"id":15084,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/14130\/revisions\/15084"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=14130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=14130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=14130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}